166 related articles for article (PubMed ID: 26661118)
1. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
[TBL] [Abstract][Full Text] [Related]
2. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
[TBL] [Abstract][Full Text] [Related]
3. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
4. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
[TBL] [Abstract][Full Text] [Related]
6. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M
Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726
[TBL] [Abstract][Full Text] [Related]
7. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Teufel M; Seidel H; Köchert K; Meinhardt G; Finn RS; Llovet JM; Bruix J
Gastroenterology; 2019 May; 156(6):1731-1741. PubMed ID: 30738047
[TBL] [Abstract][Full Text] [Related]
9. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.
Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C
Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239
[TBL] [Abstract][Full Text] [Related]
10. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
[TBL] [Abstract][Full Text] [Related]
13. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
14. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
[TBL] [Abstract][Full Text] [Related]
15. The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
Chong DQ; Tan IB; Choo SP; Toh HC
Contemp Clin Trials; 2013 Nov; 36(2):605-15. PubMed ID: 23591326
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
17. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.
Subbiah IM; Falchook GS; Kaseb AO; Hess KR; Tsimberidou AM; Fu S; Subbiah V; Hong DS; Naing A; Piha-Paul SA; Akmal O; Janku F; Kurzrock R
Oncotarget; 2015 Sep; 6(29):28453-62. PubMed ID: 26164085
[TBL] [Abstract][Full Text] [Related]
18. Intratumor heterogeneity in hepatocellular carcinoma.
Friemel J; Rechsteiner M; Frick L; Böhm F; Struckmann K; Egger M; Moch H; Heikenwalder M; Weber A
Clin Cancer Res; 2015 Apr; 21(8):1951-61. PubMed ID: 25248380
[TBL] [Abstract][Full Text] [Related]
19. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
20. [Molecular targeted agent for hepatocellular carcinoma].
Ueshima K; Kudo M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():457-62. PubMed ID: 23520633
[No Abstract] [Full Text] [Related]
[Next] [New Search]